RT Journal Article
SR Electronic
T1 Cascaded Multimodal Deep Learning in the Differential Diagnosis, Progression Prediction, and Staging of Alzheimer’s and Frontotemporal Dementia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.23.24314186
DO 10.1101/2024.09.23.24314186
A1 Guarnier, Gianmarco
A1 Reinelt, Janis
A1 Molloy, Eóin N.
A1 Mihai, Paul Glad
A1 Einaliyan, Pegah
A1 Valk, Sofie
A1 Modestino, Augusta
A1 Ugolini, Matteo
A1 Mueller, Karsten
A1 Wu, Qiong
A1 Babayan, Anahit
A1 Castellaro, Marco
A1 Villringer, Arno
A1 Scherf, Nico
A1 Thierbach, Konstantin
A1 Schroeter, Matthias L.
A1 Alzheimer’s Disease Neuroimaging Initiative
A1 the Australian Imaging Biomarkers and Lifestyle flagship study of ageing
A1 the Frontotemporal Lobar Degeneration Neuroimaging Initiative
YR 2024
UL http://medrxiv.org/content/early/2024/09/24/2024.09.23.24314186.abstract
AB Dementia syndromes are complex sequelae whose multifaceted nature poses significant challenges in the diagnosis, prognosis, and treatment of patients. Despite the availability of large open-source data fueling a wealth of promising research, effective translation of preclinical findings to clinical practice remains difficult. This barrier is largely due to the complexity of unstructured and disparate preclinical and clinical data, which traditional analytical methods struggle to handle. Novel analytical techniques involving Deep Learning (DL), however, are gaining significant traction in this regard. Here, we have investigated the potential of a cascaded multimodal DL-based system (TelDem), assessing the ability to integrate and analyze a large, heterogeneous dataset (n=7159 patients), applied to three clinically relevant use cases. Using a Cascaded Multi-Modal Mixing Transformer (CMT), we assessed TelDem’s validity and (using a Cross Modal Fusion Norm - CMFN) model explainability in (i) differential diagnosis between healthy individuals, AD, and three sub-types of frontotemporal lobar degeneration (ii) disease staging from healthy cognition to mild cognitive impairment (MCI) and AD, and (iii) predicting progression from MCI to AD. Our findings show that the CMT enhances diagnostic and prognostic accuracy when incorporating multimodal data compared to unimodal modeling and that cerebrospinal fluid (CSF) biomarkers play a key role in accurate model decision making. These results reinforce the power of DL technology in tapping deeper into already existing data, thereby accelerating preclinical dementia research by utilizing clinically relevant information to disentangle complex dementia pathophysiology.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Row Fogo Charitable Trust (grant no. BRO-D.FID3668413, MVH). This study was supported by grants from the German Research Foundation (SCHR 774/5-1 to MLS), and the eHealthSax Initiative of the Sachsische Aufbaubank (Project TelDem). Accordingly, this study was co-financed with tax revenue based on the budget approved by the Saxon state parliament.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All used data are publicly available through the https://ida.loni.usc.edu/ website.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll used data are publicly available through the https://ida.loni.usc.edu/